Starpharma signs DEP® ADC Research Agreement with MSD
News provided by
Share this article
Starpharma (ASX: SPL,OTCQX: SPHRY) today
announced that is has signed a Research Agreement with MSD, the tradename of
Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma s proprietary DEP
® technology.
Dr Jackie Fairley, CEO of Starpharma commented: MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area.
DEP
® ADCs exploit the unique potential of Starpharma s DEP